HK1161082A1 - Methods for treating reperfusion injuries - Google Patents

Methods for treating reperfusion injuries

Info

Publication number
HK1161082A1
HK1161082A1 HK12101453.4A HK12101453A HK1161082A1 HK 1161082 A1 HK1161082 A1 HK 1161082A1 HK 12101453 A HK12101453 A HK 12101453A HK 1161082 A1 HK1161082 A1 HK 1161082A1
Authority
HK
Hong Kong
Prior art keywords
methods
reperfusion injuries
treating reperfusion
treating
injuries
Prior art date
Application number
HK12101453.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrei V Gudkov
Robert Fairchild
Original Assignee
克里夫蘭生物實驗室公司
克里夫蘭臨床基金會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 克里夫蘭生物實驗室公司, 克里夫蘭臨床基金會 filed Critical 克里夫蘭生物實驗室公司
Publication of HK1161082A1 publication Critical patent/HK1161082A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK12101453.4A 2008-08-01 2012-02-15 Methods for treating reperfusion injuries HK1161082A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8576608P 2008-08-01 2008-08-01
PCT/US2009/052493 WO2010014957A1 (en) 2008-08-01 2009-07-31 Methods for treating reperfusion injuries

Publications (1)

Publication Number Publication Date
HK1161082A1 true HK1161082A1 (en) 2012-08-24

Family

ID=41610763

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101453.4A HK1161082A1 (en) 2008-08-01 2012-02-15 Methods for treating reperfusion injuries

Country Status (11)

Country Link
US (4) US8324163B2 (xx)
EP (1) EP2320948B1 (xx)
JP (1) JP5577337B2 (xx)
CN (1) CN102170911B (xx)
AU (1) AU2009276357B2 (xx)
CA (1) CA2732763A1 (xx)
EA (1) EA020579B1 (xx)
ES (1) ES2412237T3 (xx)
HK (1) HK1161082A1 (xx)
PT (1) PT2320948E (xx)
WO (1) WO2010014957A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069198A1 (en) 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
SG191830A1 (en) 2011-01-10 2013-08-30 Cleveland Biolabs Inc Use of toll-like receptor agonist for treating cancer
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP2833876A4 (en) * 2012-04-02 2015-09-09 Health Research Inc COMPOSITIONS AND METHODS FOR TOLL-LIKE RECEPTOR (TLR) -STIMULATIVE ACTIVE AGGREGATES FOR PROPHYLAXIS AND THERAPY OF DAMAGE TO THE DERMAL EPITHEL
MX2017001279A (es) * 2014-07-30 2017-08-07 Cleveland Biolabs Inc Usos y composiciones de la flagelina.
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CN109937045A (zh) * 2016-08-11 2019-06-25 天普大学-联邦高等教育系统 局部缺血/再灌注损伤
AU2018304469B2 (en) 2017-07-20 2023-04-06 Spogen Biotech Inc. Bioactive polypeptides for improvements in plant protection, growth and productivity
CN208752357U (zh) * 2018-09-21 2019-04-16 合肥京东方显示光源有限公司 背光模块及具有该背光模块的显示面板及显示器
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
EP0503012B1 (de) 1990-09-28 1996-06-26 Sulzer Innotec Ag Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
IL150885A0 (en) 2000-01-31 2003-02-12 Munin Corp Cyr61 compositions and methods
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1453467A4 (en) 2001-10-02 2008-01-09 Univ Chicago METHODS AND COMPOSITIONS FOR MODULATING APOPTOSIS
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
SG148215A1 (en) * 2003-12-02 2008-12-31 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US7638485B2 (en) * 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
US20050266391A1 (en) * 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006066214A2 (en) 2004-12-16 2006-06-22 Wake Forest University Health Sciences Use of flagellin in the immunotherapy of yersinia pestis
WO2006069198A1 (en) * 2004-12-22 2006-06-29 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
US20090306190A1 (en) * 2005-09-09 2009-12-10 Mary Stenzel-Poore Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
TR201000668T1 (tr) 2007-07-31 2010-06-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
EP2224954B1 (en) 2007-11-07 2014-01-08 Celldex Therapeutics, Inc. Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
EA021842B1 (ru) 2009-10-06 2015-09-30 Общество С Ограниченной Ответственностью "Панацела Лабс" Применение toll-подобного рецептора и агониста для лечения рака

Also Published As

Publication number Publication date
JP5577337B2 (ja) 2014-08-20
AU2009276357B2 (en) 2014-09-11
EP2320948A4 (en) 2012-01-25
CN102170911A (zh) 2011-08-31
US8324163B2 (en) 2012-12-04
ES2412237T3 (es) 2013-07-10
JP2011529922A (ja) 2011-12-15
EA020579B1 (ru) 2014-12-30
PT2320948E (pt) 2013-06-17
US20110135665A1 (en) 2011-06-09
EP2320948A1 (en) 2011-05-18
CA2732763A1 (en) 2010-02-04
US20140220037A1 (en) 2014-08-07
US8618059B2 (en) 2013-12-31
EP2320948B1 (en) 2013-03-06
US20150182587A1 (en) 2015-07-02
EA201170294A1 (ru) 2011-08-30
US9006180B2 (en) 2015-04-14
WO2010014957A1 (en) 2010-02-04
CN102170911B (zh) 2014-07-02
AU2009276357A1 (en) 2010-02-04
US20130004515A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
HK1161082A1 (en) Methods for treating reperfusion injuries
IL212348A0 (en) Treatment method
HK1167082A1 (en) Compositions and methods for treating ischemia and ischemia reperfusion injury
IL209895A0 (en) Compounds for treating beta-amyloidoses
LT2349132T (lt) Aparatas gerl gydymui
PT2248083T (pt) Método de autenticação
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
IL211774A (en) Animal Care Device
HK1203516A1 (en) Methods for treating psoriasis
GB0822011D0 (en) Treatment
EP2311711A4 (en) CONTROL UNIT
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
GB0801209D0 (en) Process
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
GB0801580D0 (en) Process
GB0811992D0 (en) Treatment
GB0800875D0 (en) Process
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
EP2292495A4 (en) STEERING APPARATUS
GB0820972D0 (en) Treatment
IL213287A0 (en) Treatment for glomerulonephritis
GB0805912D0 (en) Treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180731